Abstract: Falls are the leading cause of injuries and fatalities among older individuals propagating concerns for health and safety. Mitigating these concerns requires timely intervention and response ...

The new year could bring dramatic changes to health care. Michigan doctors highlight the top 5 things they expect to see in ...

A South Korean biomanufacturing giant is set to purchase its first drug production facility in the U.S. for a sum worthy of its tech giant parent. Samsung Biologics is the world’s largest contract ...

Already boasting an outsized presence in its home country of South Korea, CDMO juggernaut Samsung Biologics is making manufacturing inroads in the U.S. by way of an acquisition. Samsung Bio’s U.S.

SEOUL, Dec 22 (Reuters) - South Korea's Samsung Biologics (207940.KS), opens new tab said on Monday it is acquiring its first U.S. drug production facility from GSK (GSK.L), opens new tab for $280 ...

M arking a significant expansion of the company’s global footprint and long-term commitment to the U.S. market, Samsung Biologics America (SBA) has entered into an agreement with GSK to acquire 100% ...

Samsung Biologics America, a subsidiary of Samsing Biologics, a CDMO, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK for $280 million. This strategic move ...

Samsung Biologics acquires Human Genome Sciences from GSK for $280 million, expanding its US manufacturing footprint. The Rockville, MD facility adds 60,000 liters of cGMP biologics capacity, ...

Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 ...

INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing ...